Aqupla (nedaplatin)

Given the advanced stage, the patient received a systemic combination of tislelizumab, cyclophosphamide, pegylated liposomal doxorubicin, and nedaplatin, initially combined with local intrapleural therapy. This case highlights a diagnostic pitfall in lung tumors exhibiting squamoid immunophenotypes and underscores the necessity of incorporating myoepithelial markers into the diagnostic workup. Furthermore, it provides a cautiously interpreted clinical observation of immune checkpoint inhibitor-based combination therapy in advanced PACC.

P=N/A, N=15, Linfen Central Hospital; Linfen Central Hospital

The efficacy of nCIT in HPSCC is predetermined by a baseline immune architecture orchestrated by a CCL3+ neutrophil subset. The Neu_CCL3 gene signature is a promising, clinically translatable biomarker that can fill a critical gap in precision immunotherapy for HPSCC.

P=N/A, N=1, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

P2, N=62, Active, not recruiting, Sun Yat-sen University

P2, N=30, Recruiting, Zhejiang Cancer Hospital

After multiple-line treatment including chemotherapy, targeted therapy, and immunotherapy, disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy, and the adverse reactions to the therapy were tolerable.

P=N/A, N=30, Not yet recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

The patient started first-line therapy with osimertinib combined with pemetrexed/nedaplatin, resulting in a transient partial response, significant resolution of pleural effusion, and partial regression of the primary tumor. The patient achieved only transient disease control following treatment with a third-generation EGFR TKI combined with chemoradiotherapy. Further research to explore optimal therapeutic strategies for such complex molecular profiles is needed.

P2, N=118, Completed, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Enrolling by invitation --> Completed | N=62 --> 118 | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Apr 2024 --> Aug 2025

P1/2, N=86, Recruiting, Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting

P4, N=50, Not yet recruiting, Gansu Provincial Hospital; Gansu Provincial People's Hospital